Edward Jones's most recent trade in Cytosorbents Corp was a trade of 22,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 2, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytosorbents Corp | Edward R. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Jones R. Edward | Director | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 13 Dec 2023 | 7,519 | 88,834 (0%) | 0% | 1.3 | 10,000 | Common Stock |
| Cytosorbents Corp | Jones Edward R. | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Dec 2023 | 2,631 | 2,631 | - | - | Common Stock Warrant (Right to Buy) | |
| Cytosorbents Corp | Edward R. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Edward R. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 18,975 | 18,975 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Edward R. Jones | Director | Purchase of securities on an exchange or from another person at price $ 2.24 per share. | 16 May 2022 | 1,676 | 81,315 (0%) | 0% | 2.2 | 3,749 | Common Stock |
| Cytosorbents Corp | Edward R. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Edward R. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.12 per share. | 09 Dec 2021 | 4,000 | 82,800 (0%) | 0% | 4.1 | 16,500 | Common Stock |
| Cytosorbents Corp | Edward R. Jones | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.22 per share. | 09 Dec 2021 | 3,161 | 79,639 (0%) | 0% | 5.2 | 16,500 | Common Stock |
| Cytosorbents Corp | Edward R. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 17,250 | 17,250 | - | - | Stock Option (right to buy) | |
| Cytosorbents Corp | Edward R. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 18 Aug 2020 | 4,000 | 78,800 (0%) | 0% | 3.4 | 13,400 | Common Stock |
| Cytosorbents Corp | Edward R. Jones | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2020 | 4,000 | 0 | - | - | Stock Option (right to buy) |